Soru

Zorluk: ZorSubstance-Related and Addictive Disorders

A 34-year-old man with a 5-year history of severe heroin use disorder presents to an outpatient addiction clinic seeking treatment. He reports that his last heroin use was 2 hours ago. He is highly motivated to stop using illicit opioids and requests to start buprenorphine/naloxone therapy immediately. To appropriately initiate and maintain his treatment while avoiding iatrogenic complications, arrange the following management steps in the correct chronological sequence.

  1. 1Instruct the patient to delay induction until sufficient time has elapsed to allow clearance of the full agonist
  2. 2Verify the emergence of objective signs of mild-to-moderate opioid withdrawal using a standardized clinical scale
  3. 3Administer the initial sublingual test dose of buprenorphine/naloxone
  4. 4Titrate the medication dosage upward over several days to suppress illicit opioid cravings
  5. 5Establish a long-term care plan integrating maintenance pharmacotherapy with behavioral counseling

Cevap

The correct chronological sequence is to first delay the induction, verify objective signs of withdrawal, administer the initial dose, titrate the dose upward, and finally establish long-term maintenance.
Buprenorphine is a partial agonist with very high affinity for the mu-opioid receptor. If administered while a full agonist (like heroin) is still occupying the receptors, buprenorphine competitively displaces the heroin but provides less receptor activation, immediately causing severe 'precipitated withdrawal'. Therefore, the first step is to delay induction until the full agonist has cleared. Second, the clinician must objectively verify the onset of spontaneous withdrawal (e.g., using a standardized scale). Only then is the initial test dose administered. Once induction is successful, the dose is titrated to suppress cravings, followed by long-term maintenance combined with psychosocial support.

Adım Adım Çözüm

1
Identify the primary pharmacological risk in initiating buprenorphine for a patient recently exposed to heroin.
The primary risk is precipitated withdrawal due to buprenorphine's high receptor affinity and partial agonist properties.
Buprenorphine displaces heroin from mu-opioid receptors. If administered too soon, the sudden shift to a partial agonist causes an acute, severe withdrawal syndrome.
2
Determine the necessary prerequisite before the first buprenorphine dose can be administered.
The patient must wait for the full agonist to clear from their system.
Waiting (typically 12-24 hours for heroin) ensures the receptors are no longer fully occupied, mitigating the risk of precipitated withdrawal.
3
Determine how to objectively measure readiness for the first dose.
The clinician assesses the patient using a standardized tool to confirm mild-to-moderate withdrawal.
Objective signs (e.g., using the Clinical Opiate Withdrawal Scale) confirm the safe therapeutic window for induction.
4
Sequence the remaining pharmacological steps.
Following confirmation of withdrawal, the initial dose is given, and the dosage is titrated over several days to achieve craving suppression.
Induction requires careful initial dosing followed by a titration phase to find the optimal steady-state dose.
5
Identify the long-term management strategy.
Long-term maintenance integrates the stabilized pharmacotherapy with behavioral counseling.
Medication for opioid use disorder is most effective when paired with comprehensive psychosocial interventions.

Anahtar Kavram

Buprenorphine Induction and Prevention of Precipitated Withdrawal
Tahmini Süre:1m 30s
Bu soruyu puanla